Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Improving maraviroc oral bioavailability by formation of solid drug nanoparticles.

Savage AC, Tatham LM, Siccardi M, Scott T, Vourvahis M, Clark A, Rannard SP, Owen A.

Eur J Pharm Biopharm. 2019 May;138:30-36. doi: 10.1016/j.ejpb.2018.05.015. Epub 2018 May 17.

PMID:
29777772
2.

Towards a Maraviroc long-acting injectable nanoformulation.

Tatham LM, Savage AC, Dwyer A, Siccardi M, Scott T, Vourvahis M, Clark A, Rannard SP, Owen A.

Eur J Pharm Biopharm. 2019 May;138:92-98. doi: 10.1016/j.ejpb.2018.04.009. Epub 2018 Apr 21.

PMID:
29684534
3.

Long-acting injectable atovaquone nanomedicines for malaria prophylaxis.

Bakshi RP, Tatham LM, Savage AC, Tripathi AK, Mlambo G, Ippolito MM, Nenortas E, Rannard SP, Owen A, Shapiro TA.

Nat Commun. 2018 Jan 22;9(1):315. doi: 10.1038/s41467-017-02603-z.

4.

Role of highly branched, high molecular weight polymer structures in directing uniform polymer particle formation during nanoprecipitation.

Hatton FL, Chambon P, Savage AC, Rannard SP.

Chem Commun (Camb). 2016 Mar 11;52(20):3915-8. doi: 10.1039/c6cc00611f. Epub 2016 Feb 12.

PMID:
26871974
5.

Botulinum neurotoxin serotypes detected by electrochemical impedance spectroscopy.

Savage AC, Buckley N, Halliwell J, Gwenin C.

Toxins (Basel). 2015 May 6;7(5):1544-55. doi: 10.3390/toxins7051544.

6.

Peptide coated gold nanoparticles that bind lanthanide ions.

Savage AC, Pikramenou Z.

Chem Commun (Camb). 2011 Jun 14;47(22):6431-3. doi: 10.1039/c1cc11477h. Epub 2011 May 9.

PMID:
21552621

Supplemental Content

Loading ...
Support Center